Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada

Matthew A. Weir; Arsh K. Jain; Tara Gomes; David N. Juurlink; Muhammad Mamdani; Lihua Li; Amit X. Garg

doi:10.1053/j.ajkd.2010.09.025

Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada

Matthew A. Weir
, Arsh K. Jain
, Tara Gomes
, David N. Juurlink
, Muhammad Mamdani
, Lihua Li
, Amit X. Garg

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	357-359
Number of pages	3
Journal	American Journal of Kidney Diseases
Volume	57
Issue number	2
DOIs	https://doi.org/10.1053/j.ajkd.2010.09.025
State	Published - Feb 2011
Externally published	Yes

Access to Document

10.1053/j.ajkd.2010.09.025

Cite this

Weir, M. A., Jain, A. K., Gomes, T., Juurlink, D. N., Mamdani, M., Li, L., & Garg, A. X. (2011). Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada. American Journal of Kidney Diseases, 57(2), 357-359. https://doi.org/10.1053/j.ajkd.2010.09.025

@article{906b65be5e904fbebbe4cf2e53ebce5a,

title = "Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada",

author = "Weir, \{Matthew A.\} and Jain, \{Arsh K.\} and Tara Gomes and Juurlink, \{David N.\} and Muhammad Mamdani and Lihua Li and Garg, \{Amit X.\}",

note = "Funding Information: Support: This project was supported by the Lawson Health Research Institute and the Ontario Drug Policy Research Network , which receives funding from the Ontario Ministry of Health and Long-term Care (MOHLTC) Drug Innovation Fund . Dr Weir was supported by the Clinical Investigator Program Award at the University of Western Ontario and funding from the MOHLTC . Dr Garg was supported by a Clinician Scientist Award from the Canadian Institutes of Health Research . The Institute of Clinical Evaluative Sciences (ICES) receives funding from the MOHLTC . The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. ",

year = "2011",

month = feb,

doi = "10.1053/j.ajkd.2010.09.025",

language = "English",

volume = "57",

pages = "357--359",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders",

number = "2",

}

Weir, MA, Jain, AK, Gomes, T, Juurlink, DN, Mamdani, M, Li, L & Garg, AX 2011, 'Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada', American Journal of Kidney Diseases, vol. 57, no. 2, pp. 357-359. https://doi.org/10.1053/j.ajkd.2010.09.025

Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada. / Weir, Matthew A.; Jain, Arsh K.; Gomes, Tara et al.
In: American Journal of Kidney Diseases, Vol. 57, No. 2, 02.2011, p. 357-359.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Sevelamer prescriptions after reporting of the dialysis clinical outcomes revisited (DCOR) trial findings

T2 - An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada

AU - Weir, Matthew A.

AU - Jain, Arsh K.

AU - Gomes, Tara

AU - Juurlink, David N.

AU - Mamdani, Muhammad

AU - Li, Lihua

AU - Garg, Amit X.

N1 - Funding Information: Support: This project was supported by the Lawson Health Research Institute and the Ontario Drug Policy Research Network , which receives funding from the Ontario Ministry of Health and Long-term Care (MOHLTC) Drug Innovation Fund . Dr Weir was supported by the Clinical Investigator Program Award at the University of Western Ontario and funding from the MOHLTC . Dr Garg was supported by a Clinician Scientist Award from the Canadian Institutes of Health Research . The Institute of Clinical Evaluative Sciences (ICES) receives funding from the MOHLTC . The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources.

PY - 2011/2

Y1 - 2011/2

UR - https://www.scopus.com/pages/publications/78751606818

U2 - 10.1053/j.ajkd.2010.09.025

DO - 10.1053/j.ajkd.2010.09.025

M3 - Letter

C2 - 21251552

AN - SCOPUS:78751606818

SN - 0272-6386

VL - 57

SP - 357

EP - 359

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 2

ER -